New hope for Hard-to-Treat breast cancer: drug duo targets rare mutation

NCT ID NCT07193394

Recruiting now Disease control Sponsor: Institut Curie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of two drugs, tucatinib and trastuzumab, in people with a specific type of advanced breast cancer that has a mutation in the HER3 gene. The cancer must be HER2-negative and has already been treated with at least two prior chemotherapies. The goal is to see if this drug pair can shrink tumors or stop them from growing for at least 24 weeks, offering a new treatment option when few exist.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm Her2-receptor negative breast cancer neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC BREAST CANCER ( HER2 NEGATIVE) UNRESECTABLE BREAST CANCER

Contacts and locations

Locations

CHU de Nîmes
NOT_YET_RECRUITING

Nîmes, 30 029, France
Centre Antoine Lacassagne
NOT_YET_RECRUITING

Nice, 06 189, France
Centre Eugène Marquis
NOT_YET_RECRUITING

Rennes, 35 042, France
Chu Dupuytren- Limoges
NOT_YET_RECRUITING

Limoges, 87 042, France
Institut Curie_ Site Saint-Cloud
RECRUITING

Saint-Cloud, 92 210, France
Institut Paoli-Calmettes
NOT_YET_RECRUITING

Marseille, 13009, France
Institut Universitaire du Cancer de Toulouse (IUCT) - Oncopole Claudius Regaud
NOT_YET_RECRUITING

Toulouse, 31 059, France
Institut de Cancérologie de Lorraine
NOT_YET_RECRUITING

Vandœuvre-lès-Nancy, 54 519, France
Polyclinique Bordeaux Nord Aquitaine
NOT_YET_RECRUITING

Bordeaux, 33 300, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.